Post by trenddiver on Feb 26, 2015 20:42:57 GMT -5
In 2012, Mannkind licensed MLC1106, its active immunotherapy program to Colby Pharmaceuticals for cash, milestones and a back end royalty. I also believe that MNKD had certain repurchase rights. It would be nice to know the status of this. I remember MNKD was kind of disappointed they had to give it up to save cash during the dark days.
Trend